Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.49 is 463% above its 5-year average of -0.14, near the high end of its 5-year range (-0.86–0.61).
753.33% above its 12-month average of -0.07.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.18.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:15:40.350Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.49
EARNINGS PER SHARE (EPS) AVG TTM
-0.07
EARNINGS PER SHARE (EPS) AVG 3Y
-0.37
EARNINGS PER SHARE (EPS) AVG 5Y
-0.14
EARNINGS PER SHARE (EPS) AVG 10Y
0.13
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+753.33%
CURRENT VS 3Y AVG
+231.54%
CURRENT VS 5Y AVG
+462.96%
CURRENT VS 10Y AVG
+271.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Amneal Pharmaceuticals, Inc.
Market Cap
$6.47B
Earnings Per Share (EPS)
0.49
TTM Avg
-0.07
3Y Avg
-0.37
5Y Avg
-0.14
Market Cap
$6.51B
Earnings Per Share (EPS)
-0.63
TTM Avg
0.57
3Y Avg
0.18
5Y Avg
-0.06
Market Cap
$6.53B
Earnings Per Share (EPS)
4.14
TTM Avg
3.99
3Y Avg
3.29
5Y Avg
1.98
Market Cap
$6.50B
Earnings Per Share (EPS)
-9.75
TTM Avg
-37.33
3Y Avg
-73.93
5Y Avg
-56.40
Market Cap
$6.65B
Earnings Per Share (EPS)
-2.82
TTM Avg
-2.75
3Y Avg
-2.27
5Y Avg
-1.96
Market Cap
$6.65B
Earnings Per Share (EPS)
19.92
TTM Avg
19.26
3Y Avg
18.34
5Y Avg
18.42
Market Cap
$6.01B
Earnings Per Share (EPS)
9.35
TTM Avg
3.11
3Y Avg
1.82
5Y Avg
1.76
Market Cap
$5.89B
Earnings Per Share (EPS)
-0.70
TTM Avg
-1.19
3Y Avg
-1.69
5Y Avg
-1.81
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.47B | 0.49 | -0.07 | -0.37 | -0.14 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.51B | -0.63 | 0.57 | 0.18 | -0.06 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 4.14 | 3.99 | 3.29 | 1.98 |
| GRAIL Inc. (GRAL)vs › | $6.50B | -9.75 | -37.33 | -73.93 | -56.40 |
| Immunovant, Inc. (IMVT)vs › | $6.65B | -2.82 | -2.75 | -2.27 | -1.96 |
| Chemed Corporation (CHE)vs › | $6.65B | 19.92 | 19.26 | 18.34 | 18.42 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.01B | 9.35 | 3.11 | 1.82 | 1.76 |
| Alkermes plc (ALKS)vs › | $6.98B | 0.38 | 1.85 | 1.22 | 0.64 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.89B | -0.70 | -1.19 | -1.69 | -1.81 |
| CG Oncology Inc. (CGON)vs › | $5.77B | -2.70 | -1.75 | -1.29 | -1.09 |
Trailing EPS (TTM)
$0.49
Forward EPS (Est.)
$1.02
P/E Ratio
41.6
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.23 |
| 2024-12-31 | -0.38 |
| 2023-12-31 | -0.48 |
| 2022-12-31 | -0.86 |
| 2021-12-31 | 0.07 |
| 2020-12-31 | 0.61 |
| 2018-12-31 | -1.33 |
| 2017-12-31 | 1.46 |
| 2016-12-31 | 1.10 |
| 2015-12-31 | 0.90 |
| 2014-12-31 | 0.94 |
